Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Dr. Mehta on Rationale for a Phase II Trial of TAS-102/Ramucirumab in Gastric/GEJ Cancer

June 19th 2019

Rutika Mehta, MD, MPH, gastrointestinal medical oncologist, Moffitt Cancer Center, discusses the rationale and design of a phase II study of TAS-102 (trifluridine/tipiracil; Lonsurf) in combination with ramucirumab (Cyramza) in patients with advanced, refractory gastric or gastroesophageal junction (GEJ) adenocarcinoma (NCT03686488).

Dr. Hall on the Importance of Genetic Testing in Pancreatic Cancer

June 19th 2019

Michael J. Hall, MD, MS, chair, Department of Clinical Genetics, director, Gastrointestinal Risk Assessment, associate professor, Fox Chase Cancer Center, discusses the importance of genetic testing in pancreatic cancer.

Pfizer Acquires Array BioPharma in $11.4 Billion Deal

June 18th 2019

Pfizer Inc. has entered into a definitive merger agreement with Array BioPharma, in which Pfizer will acquire Array BioPharma for $48 per share in cash, leading to a total enterprise value of an estimated $11.4 billion.

Dr. Bekaii-Saab on Tolerability of Encorafenib, Binimetinib, and Cetuximab in BRAF+ CRC

June 17th 2019

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the tolerability of encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.

Ongoing Challenges and Future Directions of Therapy in HCC

June 17th 2019

Promising Combination Therapy Approaches in HCC

June 17th 2019

Merging Treatments for HCC Into a Sequencing Strategy

June 17th 2019

Hepatocellular Carcinoma: Changes to Clinical Guidelines

June 17th 2019

Reimbursement Considerations in Hepatocellular Carcinoma

June 17th 2019

Safety/Efficacy Experience With Ramucirumab in HCC

June 17th 2019

VEGF-Targeted Therapy in HCC: Ramucirumab

June 17th 2019

Approval-Inciting Data in Hepatocellular Carcinoma

June 17th 2019

Selecting Second-Line Therapy in Hepatocellular Carcinoma

June 17th 2019

Selecting Frontline Multikinase Inhibition in HCC

June 17th 2019

Hepatocellular Carcinoma: Switching to Systemic Therapy

June 17th 2019

Optimal Approaches to Liver-Directed Therapy in HCC

June 17th 2019

Discerning Locoregional Therapy's Role in HCC Management

June 17th 2019

Hepatocellular Carcinoma: AFP's Role as a Biomarker

June 17th 2019

Progress in the Management of Hepatocellular Carcinoma

June 17th 2019

Tumor Sidedness Opens Door for Personalized Therapy in Colorectal Cancer

June 17th 2019

Sujatha Nallapareddy, MD, discusses how personalized therapy has improved the outlook for patients with colorectal cancer and sheds light on some of the challenges that lie ahead.